Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. - sprookjes - yvandenbroek - TriplyDB

Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine.

Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine.

http://www.wikidata.org/entity/Q38004869

about

Adapting Drug Approval Pathways for Bacteriophage-Based Therapeutics Phage cocktails and the future of phage therapy Taking bacteriophage therapy seriously: a moral argument Quality and safety requirements for sustainable phage therapy products.Call for a dedicated European legal framework for bacteriophage therapy.Novel avenues for Clostridium difficile infection drug discovery.Exploring the risks of phage application in the environment.Phage approved in food, why not as a therapeutic?Silk route to the acceptance and re-implementation of bacteriophage therapy.Bacteriophage therapy: a regulatory perspective.Phage Therapy: Future Inquiries.Novel approach of using a cocktail of designed bacteriophages against gut pathogenic E. coli for bacterial load biocontrol.Bacteriophages and Biofilms.Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler.Are Phage Lytic Proteins the Secret Weapon To Kill Staphylococcus aureus?Guidelines for Bacteriophage Product Certification.Bacteriophage Production in Compliance with Regulatory Requirements.Bacteriophage therapy: practicability and clinical need meet in the multidrug-resistance era.Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy-Part II.Criteria for Selecting Suitable Infectious Diseases for Phage Therapy.

P2860

Q26740597-53BEE633-D498-45C1-88B0-0F43818D8EB0 Q26995797-F3611AF2-8FD2-49DE-ACE1-28CC7BB03B9F Q33608714-BD49CE31-3D67-4BF4-B38A-EDAD07774EAE Q35674419-3B0B7D9A-E9B2-4D7E-B909-6C9373890987 Q37631618-9D241594-4AC1-4B36-9079-2D3D5913C4B6 Q38083297-EB45588C-5553-42B4-8CDE-19EC70AA7B2A Q38172129-F4DD4AFD-06C8-4F80-AE13-C6EFBC9C4024 Q38285489-CEAF4C50-2DA4-4DEB-AE5A-D40C306A6FCF Q38381910-6865D7BA-7B2B-41A5-A71B-1DFE38958FEF Q38805538-957F81D9-8280-4F5B-BEE7-FD6830D43588 Q38911928-9C97F9F1-A45F-4506-97FF-B03435CE555A Q42203724-C517B580-9187-42C7-A881-D58B98D5701A Q46790139-1FBB54F1-CAEF-4B2C-B030-BD3C4FEA172D Q47990285-06A1359B-66B0-4C16-8FB7-75CEFF1FF01C Q48181608-D69F24DB-CFF4-40D9-80CB-D51DC52211C7 Q48606487-15404105-CE79-48C8-B631-9F944B4B7C51 Q50100571-B160AFA3-3ECB-4212-9005-8B7A8EBCFB5E Q51574166-7D9EC3A3-BD31-4D36-8016-3434CBE27884 Q52431831-5020D5AA-60F4-4B74-9A47-AA4EE080280D Q53075476-6D2756DB-FF0E-4272-8082-3A3EE6F768EA

P2860

Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine.

http://www.wikidata.org/entity/Q38004869

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Optimizing the European regula ...... age therapy in human medicine.

@en

type

label

Optimizing the European regula ...... age therapy in human medicine.

@en

prefLabel

Optimizing the European regula ...... age therapy in human medicine.

@en

P1433

Q38004869-D770AA8D-BF39-4174-8418-7F3E0528E28C

P1476

Q38004869-5E42ABEA-CD37-4EF7-926A-70AAAD819046

P2093

Q38004869-26A2149B-4FAB-43BF-AEBB-89099CD30ADB

Q38004869-627823E8-7C1C-4739-919B-EEBB2CB65849

Q38004869-7DB750E3-035A-49FC-965C-BA8F9173934C

Q38004869-9047C26D-CB42-484B-86CC-2839E03514FB

Q38004869-AC53CCD8-D04E-4E6D-B452-9B8ADBED3BB4

P2860

Q38004869-0662BE39-2FC5-4BDA-9F39-34038E046D60

Q38004869-082FA9B4-2E36-4D6B-86CD-2AE83B90BAAD

Q38004869-0B2D986D-220A-41A0-9357-7E57B9AEED34

Q38004869-17B7159D-2B64-4D24-9F48-6BCF6B2F4BC2

Q38004869-217B468F-C73D-47D5-BE0D-94008D4C1998

Q38004869-2DF9DEC9-9739-491C-9296-C4D45FC37F1A

Q38004869-40E70806-9D11-4608-829B-72B54F5F379F

Q38004869-54FD2430-B643-48F1-B34B-AEAE8190570C

Q38004869-5536273D-22EB-4A73-9A85-5DB9A2740CEB

Q38004869-56E241E1-E07A-40AF-B7F6-4CEA7A836EBF

P2888

Q38004869-BF7C2458-C01A-4C24-B90F-8D3A9174842A

P304

Q38004869-C94AF3DF-702E-4FCB-BD36-826983880A50

P31

Q38004869-16AC293F-D891-48E1-A9D2-F8BD69B52518

P356

Q38004869-D4AF96B7-DC63-4C94-820D-43B396459C6F

P433

Q38004869-5152D51B-5F10-4495-ACE7-1DEFAED44B8A

P478

Q38004869-CB47660C-8DC1-4374-8541-BCA80B7080E2

P50

Q38004869-0133E40E-BA8B-43E0-8FE4-BB672C0FA3B0

Q38004869-2B3ECC6F-D759-491D-A3DB-267C4172DC14

Q38004869-A27AA134-A763-4124-AB03-ABE30E53AC45

P577

Q38004869-BBD560FD-6CAE-43E0-966E-C3EFE1D8A817

P5875

Q38004869-34C32F84-56CE-421F-9BAB-5E47ACCC137C

P6179

Q38004869-5311B299-2A1D-4477-8406-86B76D44712B

P698

Q38004869-87EE6379-F493-4DC3-BC63-A1FCBC852C0B

P921

Q38004869-D69524BB-B326-4CFC-8E61-DAB85D899AC5

P356

S00005-012-0175-0

P1433

Archivum Immunologiae et Therapiae Experimentalis

P1476

Optimizing the European regula ...... age therapy in human medicine.

@en

P2093

Daniel De Vos

http://www.w3.org/2001/XMLSchema#string

Gilbert Verbeken

http://www.w3.org/2001/XMLSchema#string

Jean-Paul Pirnay

http://www.w3.org/2001/XMLSchema#string

Martin Zizi

http://www.w3.org/2001/XMLSchema#string

Serge Jennes

http://www.w3.org/2001/XMLSchema#string

P2860

Phage Therapy in Clinical Practice: Treatment of Human Infections

A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa ; a preliminary report of efficacy

Bacteriophage therapy

Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials.

Phage therapy experience at the Eliava Institute.

The perspectives of the application of phage therapy in chronic bacterial prostatitis.

Phage treatment of human infections.

Old dogma, new tricks--21st Century phage therapy.

Tackling antibiotic resistance.

European regulatory conundrum of phage therapy.

P2888

s00005-012-0175-0

P304

161-172

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00005-012-0175-0

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224820262

http://www.w3.org/2001/XMLSchema#string

P6179

1018937671

http://www.w3.org/2001/XMLSchema#string

P698

22527355

http://www.w3.org/2001/XMLSchema#string

P921